Piper Sandler upgraded Xencor (XNCR) to Overweight from Neutral with a price target of $30, up from $20. Xencor is expanding its XmAb technology into autoimmune disease and will report initial Phase I healthy volunteer data on XmAb942 in the first half of 2025, the analyst tells investors in a research note. The firm tells investors to own the shares into the 2025 data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
Questions or Comments about the article? Write to editor@tipranks.com